Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Depreciation and Depletion: 2023-2025

Historic Depreciation and Depletion for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to $39,000.

  • Mereo BioPharma Group's Depreciation and Depletion fell 61.00% to $39,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $159,000, marking a year-over-year decrease of 49.04%. This contributed to the annual value of $143,000 for FY2024, which is 28.50% down from last year.
  • Mereo BioPharma Group's Depreciation and Depletion amounted to $39,000 in Q3 2025, which was down 11.36% from $44,000 recorded in Q2 2025.
  • Over the past 5 years, Mereo BioPharma Group's Depreciation and Depletion peaked at $100,000 during Q2 2023, and registered a low of $38,000 during Q4 2024.
  • For the 3-year period, Mereo BioPharma Group's Depreciation and Depletion averaged around $64,818, with its median value being $44,000 (2025).
  • Data for Mereo BioPharma Group's Depreciation and Depletion shows a maximum YoY tumbled of 61.00% (in 2025) over the last 5 years.
  • Over the past 3 years, Mereo BioPharma Group's Depreciation and Depletion (Quarterly) stood at $71,000 in 2023, then slumped by 46.48% to $38,000 in 2024, then crashed by 61.00% to $39,000 in 2025.
  • Its last three reported values are $39,000 in Q3 2025, $44,000 for Q2 2025, and $38,000 during Q1 2025.